In a patient with depression and passive suicidal ideation who is currently taking citalopram 40 mg, quetiapine (Seroquel) 75 mg at bedtime, trazodone 50 mg at bedtime, and memantine (Namenda) 10 mg daily, what medication should be prescribed?

Augment Citalopram with Bupropion or Switch to a Different Antidepressant

For this patient with depression and passive suicidal ideation on citalopram 40 mg (already at maximum dose), the most evidence-based approach is to augment with bupropion or switch to a different second-generation antidepressant (sertraline, venlafaxine). Given the presence of suicidal ideation, close monitoring is critical, and modification of treatment is warranted since the patient has not achieved adequate response on current therapy.

Rationale for Treatment Modification

The patient is already on citalopram 40 mg daily, which is the maximum FDA-approved dose 1. Since depression with passive suicidal ideation persists, this represents treatment failure requiring intervention within 6-8 weeks of inadequate response 2, 3.

Evidence-Based Options

Augmentation Strategy:

• Bupropion augmentation of citalopram showed decreased depression severity compared to buspirone augmentation, with lower discontinuation rates due to adverse events 3
• Augmentation allows continuation of partial response to citalopram while adding a different mechanism of action
• Bupropion has the advantage of lower sexual dysfunction rates compared to SSRIs 2, which may improve medication adherence

Switching Strategy:

• Switch to sertraline, bupropion, or venlafaxine - moderate-quality evidence shows no difference in response rates when switching between second-generation antidepressants 3
• Switching may be preferred if citalopram provides no benefit or causes intolerable side effects

Critical Safety Considerations for Suicidal Ideation

Monitoring Requirements

Immediate and intensive monitoring is mandatory 2:

• Assess patient status within 1-2 weeks of any medication change
• Monitor specifically for emergence of agitation, irritability, unusual behavioral changes, or worsening suicidal thoughts
• Risk for suicide attempts is greatest during the first 1-2 months of antidepressant treatment 2
• SSRIs (including citalopram) are associated with increased risk for nonfatal suicide attempts compared to placebo 2

Role of Current Medications

The patient's current regimen includes:

• Quetiapine 75 mg HS: Low dose, likely for sleep/mood stabilization. Evidence suggests quetiapine may reduce irritability and suicide risk in agitated depression 4, 5, though this dose is subtherapeutic for depression treatment
• Trazodone 50 mg HS: For sleep
• Memantine 10 mg: Suggests possible cognitive concerns or dementia

Consider increasing quetiapine to therapeutic antidepressant doses (150-300 mg/day) as adjunctive therapy if augmentation/switching strategies fail 6. Quetiapine XR has evidence for reducing suicidal ideation in MDD 5.

Specific Prescribing Recommendations

Option 1: Augment with Bupropion (Preferred)

• Start bupropion 37.5 mg every morning
• Increase by 37.5 mg every 3 days as tolerated
• Target dose: 150 mg twice daily (give second dose before 3 PM to minimize insomnia) 6
• Continue citalopram 40 mg
• Contraindications: Seizure disorders, agitated patients 6

Option 2: Switch to Different SSRI/SNRI

• Sertraline: Start 25-50 mg daily, maximum 200 mg daily 6
• Venlafaxine: Start 37.5 mg once or twice daily, increase by 75 mg weekly to 150-225 mg/day 6, 7
• Taper citalopram over 10-14 days to limit withdrawal symptoms 6

Option 3: Consider Lithium Augmentation

• If above strategies fail, lithium augmentation has specific anti-suicidal effects 8
• Start 150 mg daily, target blood level 0.2-0.6 mEq/L 6
• Requires therapeutic serum levels for anti-suicidal benefit 8

Common Pitfalls to Avoid

1. Do not continue current regimen unchanged - passive suicidal ideation with inadequate response mandates treatment modification 2, 3

2. Do not abruptly discontinue citalopram - taper over 10-14 days to prevent withdrawal syndrome 6

3. Do not combine with MAOIs - absolute contraindication due to serotonin syndrome risk 1

4. Monitor for serotonin syndrome when combining serotonergic agents (citalopram + trazodone already present) 1

5. Do not assume antidepressants alone reduce suicide risk - evidence shows SSRIs may increase suicide attempts even while improving depression 2. Close monitoring is essential.

6. Assess for bipolar disorder before intensifying antidepressant therapy - antidepressants alone may precipitate manic episodes in unrecognized bipolar disorder 1

Duration of Treatment

Once adequate response achieved:

• Continue treatment for 4-9 months minimum for first episode 2
• Longer duration (potentially indefinite) if this represents second or more depressive episode 2